ENTBF (Entheon Biomedical) Short-Term Debt: $0.00 Mil (As of Feb. 2026)


What is Entheon Biomedical Short-Term Debt?

Entheon Biomedical ENTBF Short-Term Debt is $0.00 Mil as of Feb. 2026. The stock has 2 warning signs investors should review.

Entheon Biomedical's Short-Term Debt for the quarter that ended in Feb. 2026 was $0.00 Mil.

Entheon Biomedical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Entheon Biomedical Short-Term Debt Related Terms

Entheon Biomedical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Entheon Biomedical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical Short-Term Debt Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23 Nov24 Nov25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Entheon Biomedical (ENTBF) has a Short-Term Debt of $0.00 Mil as of Feb. 2026.
Is Entheon Biomedical's Short-Term Debt too high?
Entheon Biomedical's current Short-Term Debt is $0.00 Mil.
How does Entheon Biomedical's Short-Term Debt compare to VRTX and REGN?
Entheon Biomedical's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Entheon Biomedical's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current Short-Term Debt is $0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entheon Biomedical Business Description

Other Exchanges 1XU:GermanyENBI.X:Canada
Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company focused on treating addiction and substance use disorders.